Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) EBIT (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed EBIT for 16 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT fell 18.38% to -$1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.7 million, a 11.51% decrease, with the full-year FY2024 number at -$5.8 million, down 42.35% from a year prior.
  • EBIT was -$1.3 million for Q3 2025 at NovaBay Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$5000.0 in Q3 2023 to a low of -$9.4 million in Q4 2022.
  • A 5-year average of -$2.0 million and a median of -$1.6 million in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: soared 98.91% in 2023, then tumbled 21120.0% in 2024.
  • NovaBay Pharmaceuticals' EBIT stood at -$3.2 million in 2021, then plummeted by 195.12% to -$9.4 million in 2022, then skyrocketed by 89.31% to -$1.0 million in 2023, then surged by 77.38% to -$228000.0 in 2024, then plummeted by 450.88% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's EBIT are -$1.3 million (Q3 2025), -$1.9 million (Q2 2025), and -$3.3 million (Q1 2025).